Clinical Trial

Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry

Study acronym: COPD in LCS
Recruiting
View on ClinicalTrials.gov →
Summary
The COPD in LCS Registry will identify and characterize individuals who have functional or radiographic evidence of COPD and are receiving lung cancer screening. Clinical information will be obtained from study participants including symptom burden, lung cancer risk, spirometry, imaging characteristics, and peripheral blood eosinophils.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-07.
Trial Details
NCT Number NCT06974981
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators: AstraZeneca
Conditions COPD, Chronic Obstructive Pulmonary Disease
Enrollment 420 participants
Start Date 2025-01-02
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-03